Results 211 to 220 of about 83,301 (328)

Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter study

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 2, Page 227-239, February 2026.
Abstract Aim To assess the longitudinal attainment of patient‐centered, function‐related Goal Attainment Scaling Total (GAS T)‐score after repeated abobotulinumtoxinA (AboBoNT‐A) injections over a period of up to 30 months and up to 10 cycles. Method In this prospective observational study, the investigators' clinical practices recruited patients aged ...
Mark E. Gormley   +7 more
wiley   +1 more source

Identification of Symptom Clusters in Patients With Chronic Venous Leg Ulcers [PDF]

open access: bronze, 2013
Helen Edwards   +6 more
openalex   +1 more source

Prevalence and predictors of combined >50% iliocaval venous obstruction and superficial venous reflux in chronic venous insufficiency patients with healed or active venous leg ulcer. [PDF]

open access: yesJ Vasc Surg Venous Lymphat Disord, 2023
Chinchalongporn W   +10 more
europepmc   +1 more source

Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 116-128, February 2026.
ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli   +5 more
wiley   +1 more source

MSC‐Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges—A Narrative Review

open access: yesInternational Journal of Dermatology, Volume 65, Issue 2, Page 257-272, February 2026.
ABSTRACT Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell‐based therapies.
Marcela da Costa Pereira Cestari   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy